Cart
sales@molnova.com
Sulcardine sulfate
CAS No. 343935-61-5
Sulcardine sulfate( —— )
Catalog No. M34432 CAS No. 343935-61-5
Sulcardine sulfate (B-87823) is a multi-ion channel blocker with antiarrhythmic activity, inhibits Na+, K+ and Ca2+ channels, and inhibits hNav1.5 channels in a concentration-dependent and reversible manner.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 686 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSulcardine sulfate
-
NoteResearch use only, not for human use.
-
Brief DescriptionSulcardine sulfate (B-87823) is a multi-ion channel blocker with antiarrhythmic activity, inhibits Na+, K+ and Ca2+ channels, and inhibits hNav1.5 channels in a concentration-dependent and reversible manner.
-
DescriptionSulcardine sulfate (B-87823) is a multi-ion channel blocker with antiarrhythmic activity, inhibits Na+, K+ and Ca2+ channels, and inhibits hNav1.5 channels in a concentration-dependent and reversible manner.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPotassium Channel
-
RecptorPotassium Channel | Calcium Channel | Sodium Channel
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number343935-61-5
-
Formula Weight557.68
-
Molecular FormulaC24H35N3O8S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=S(=O)(O)O.O=S(=O)(NCC=1C=C(C(O)=C(C1)CN2CCCC2)CN3CCCC3)C4=CC=C(OC)C=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
UK 78282 hydrochlori...
UK 78282 hydrochloride, a novel potent and selective Kv1.3 blocker.UK 78282 hydrochloride inhibits Kv1.3 voltage-gated potassium channels and suppresses human T cell activation.
-
NS 1619
NS1619 have been reported to have cardio-protective effects after ischemic-reperfusion injury.
-
BMS-813160
BMS-813160 is the first dual?CCR2/CCR5?antagonist to enter Clinical development for cardiovascular.
